Adipose-Derived Stem Cells Primed with Paclitaxel Inhibit Ovarian Cancer Spheroid Growth and Overcome Paclitaxel Resistance
Abstract
:1. Introduction
2. Material and Methods
2.1. Drugs
2.2. Cell Culture
2.3. PTX-Uptake and Release by ADSCs in Conditioned Medium (CM)
2.4. Cytotoxicity, Proliferation and Cell Cycles of ADSCs and PTX-ADSCs
2.5. Fluorescence-Assisted Transmigration Invasion and Motility Assay of ADSCs and PTX-ADSCs
2.6. Cocultivation of ADSCs with Ovarian Cancer Cells in Two Dimensional (2D) and Three Dimensional (3D) (Heterospherical) Models
2.7. Cultivation of Ovarian Cancer Cells as a 2D Model in the Presence of ADSC-CM
2.8. Cultivation of Ovarian Cancer Cells as a 3D Model (MCTSs) in the Presence of ADSC-CM
2.9. Migration (2D) and Dissemination/Invasion Assay
2.10. Statistical Analyses
3. Results
3.1. The Effect of PTX Uptake on ADSCs’ Activities
3.2. PTX-ADSCs Inhibit OvCa Growth
3.3. PTX-ADSCs-CM is More Active than Free PTX and Overcomes PTX-Resistance in 2D Cultures
3.4. PTX-ADSC-CM Inhibits OvCa Cell Migration
3.5. PTX-ADSC-CM is More Active than Free PTX in 3D MCTSs and Overcomes PTX Resistance
3.6. PTX-ADSC-CM Inhibits OvCa MCTS Migration/Dissemination.
4. Discussion
Supplementary Materials
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Krueger, T.E.G.; Thorek, D.L.J.; Denmeade, S.R.; Isaacs, J.T.; Brennen, W.N. Concise review: Mesenchymal stem cell-based drug delivery: The good, the bad, the ugly, and the promise. Stem Cells Transl. Med. 2018, 7, 651–663. [Google Scholar] [PubMed] [Green Version]
- Cheng, S.; Nethi, S.K.; Rathi, S.; Layek, B.; Prabha, S. Engineered mesenchymal stem cells for targeting solid tumors: Therapeutic potential beyond regenerative therapy. J. Pharmacol. Exp. Ther. 2019, 370, 231–241. [Google Scholar] [PubMed]
- Bonomi, A.; Cocce, V.; Cavicchini, L.; Sisto, F.; Dossena, M.; Balzarini, P.; Portolani, N.; Ciusani, E.; Parati, E.; Alessandri, G.; et al. Adipose tissue-derived stromal cells primed in vitro with paclitaxel acquire anti-tumor activity. Int. J. Immunopathol. Pharmacol. 2013, 26, 33–41. [Google Scholar] [PubMed]
- Nakamura, K.; Sawada, K.; Kobayashi, M.; Miyamoto, M.; Shimizu, A.; Yamamoto, M.; Kinose, Y.; Kimura, T. Role of the exosome in ovarian cancer progression and its potential as a therapeutic target. Cancers 2019, 11, 1147. [Google Scholar]
- Pascucci, L.; Cocce, V.; Bonomi, A.; Ami, D.; Ceccarelli, P.; Ciusani, E.; Vigano, L.; Locatelli, A.; Sisto, F.; Doglia, S.M.; et al. Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: A new approach for drug delivery. J. Control. Release 2014, 192, 262–270. [Google Scholar]
- Melzer, C.; Rehn, V.; Yang, Y.; Bahre, H.; von der Ohe, J.; Hass, R. Taxol-loaded MSC-derived exosomes provide a therapeutic vehicle to target metastatic breast cancer and other carcinoma cells. Cancers 2019, 11, 798. [Google Scholar]
- Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2019. CA Cancer J. Clin. 2019, 69, 7–34. [Google Scholar]
- Crivelli, B.; Chlapanidas, T.; Perteghella, S.; Lucarelli, E.; Pascucci, L.; Brini, A.T.; Ferrero, I.; Marazzi, M.; Pessina, A.; Torre, M.L. Mesenchymal stem/stromal cell extracellular vesicles: From active principle to next generation drug delivery system. J. Control. Release 2017, 262, 104–117. [Google Scholar]
- Wiklander, O.P.B.; Brennan, M.A.; Lotvall, J.; Breakefield, X.O.; El, A.S. Advances in therapeutic applications of extracellular vesicles. Sci. Transl. Med. 2019, 11, eaav8521. [Google Scholar]
- Van, N.G.; D’Angelo, G.; Raposo, G. Shedding light on the cell biology of extracellular vesicles. Nat. Rev. Mol. Cell Biol. 2018, 19, 213–228. [Google Scholar]
- Gudbergsson, J.M.; Jonsson, K.; Simonsen, J.B.; Johnsen, K.B. Systematic review of targeted extracellular vesicles for drug delivery—Considerations on methodological and biological heterogeneity. J. Control. Release 2019, 306, 108–120. [Google Scholar]
- Cortez, A.J.; Tudrej, P.; Kujawa, K.A.; Lisowska, K.M. Advances in ovarian cancer therapy. Cancer Chemother. Pharmacol. 2018, 81, 17–38. [Google Scholar] [PubMed] [Green Version]
- Coleman, R.L.; Monk, B.J.; Sood, A.K.; Herzog, T.J. Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat. Rev. Clin. Oncol. 2013, 10, 211–224. [Google Scholar] [PubMed] [Green Version]
- Lee, J.M.; Mhawech-Fauceglia, P.; Lee, N.; Parsanian, L.C.; Lin, Y.G.; Gayther, S.A.; Lawrenson, K. A three-dimensional microenvironment alters protein expression and chemosensitivity of epithelial ovarian cancer cells in vitro. Lab. Invest. 2013, 93, 528–542. [Google Scholar] [PubMed] [Green Version]
- Chiu, H.W.; Chang, J.S.; Lin, H.Y.; Lee, H.H.; Kuei, C.H.; Lin, C.H.; Huang, H.M.; Lin, Y.F. FBXL7 upregulation predicts a poor prognosis and associates with a possible mechanism for paclitaxel resistance in ovarian cancer. J. Clin. Med. 2018, 7, 330. [Google Scholar]
- Pessina, A.; Bonomi, A.; Cocce, V.; Invernici, G.; Navone, S.; Cavicchini, L.; Sisto, F.; Ferrari, M.; Vigano, L.; Locatelli, A.; et al. Mesenchymal stromal cells primed with paclitaxel provide a new approach for cancer therapy. PLoS ONE 2011, 6, e28321. [Google Scholar]
- Corona, G.; Elia, C.; Casetta, B.; Frustaci, S.; Toffoli, G. High-throughput plasma docetaxel quantification by liquid chromatography-tandem mass spectrometry. Clin. Chim. Acta. 2011, 412, 358–364. [Google Scholar]
- Chou, T.C.; Talalay, P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984, 22, 27–55. [Google Scholar]
- Spessotto, P.; Lacrima, K.; Nicolosi, P.A.; Pivetta, E.; Scapolan, M.; Perris, R. Fluorescence-based assays for in vitro analysis of cell adhesion and migration. Methods Mol. Biol. 2009, 522, 221–250. [Google Scholar]
- Casagrande, N.; Borghese, C.; Visser, L.; Mongiat, M.; Colombatti, A.; Aldinucci, D. CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth. Haematologica 2019, 104, 564–575. [Google Scholar]
- Dolznig, H.; Rupp, C.; Puri, C.; Haslinger, C.; Schweifer, N.; Wieser, E.; Kerjaschki, D.; Garin-Chesa, P. Modeling colon adenocarcinomas in vitro a 3D co-culture system induces cancer-relevant pathways upon tumor cell and stromal fibroblast interaction. Am. J. Pathol. 2011, 179, 487–501. [Google Scholar] [PubMed]
- Casagrande, N.; Celegato, M.; Borghese, C.; Mongiat, M.; Colombatti, A.; Aldinucci, D. Preclinical activity of the liposomal Cisplatin lipoplatin in ovarian cancer. Clin. Cancer Res. 2014, 20, 5496–5506. [Google Scholar] [PubMed] [Green Version]
- Casagrande, N.; De Paoli, M.; Celegato, M.; Borghese, C.; Mongiat, M.; Colombatti, A.; Aldinucci, D. Preclinical evaluation of a new liposomal formulation of cisplatin, lipoplatin, to treat cisplatin-resistant cervical cancer. Gynecol. Oncol. 2013, 131, 744–752. [Google Scholar]
- Ghoneum, A.; Afify, H.; Salih, Z.; Kelly, M.; Said, N. Role of tumor microenvironment in the pathobiology of ovarian cancer: Insights and therapeutic opportunities. Cancer Med. 2018, 7, 5047–5056. [Google Scholar] [PubMed]
- Chu, Y.; You, M.; Zhang, J.; Gao, G.; Han, R.; Luo, W.; Liu, T.; Zuo, J.; Wang, F. Adipose-derived mesenchymal stem cells enhance ovarian cancer growth and metastasis by increasing thymosin beta 4X-linked expression. Stem Cells Int. 2019, 2019, 9037197. [Google Scholar] [PubMed] [Green Version]
- Yang, J.; Zaman, M.M.; Vlasakov, I.; Roy, R.; Huang, L.; Martin, C.R.; Freedman, S.D.; Serhan, C.N.; Moses, M.A. Adipocytes promote ovarian cancer chemoresistance. Sci. Rep. 2019, 9, 13316–49649. [Google Scholar]
- Pokhriyal, R.; Hariprasad, R.; Kumar, L.; Hariprasad, G. Chemotherapy resistance in advanced ovarian cancer patients. Biomark. Cancer 2019, 11, 1179299X19860815. [Google Scholar]
- Yusuf, R.Z.; Duan, Z.; Lamendola, D.E.; Penson, R.T.; Seiden, M.V. Paclitaxel resistance: Molecular mechanisms and pharmacologic manipulation. Curr. Cancer Drug Targets 2003, 3, 1–19. [Google Scholar]
- Melling, G.E.; Carollo, E.; Conlon, R.; Simpson, J.C.; Carter, D.R.F. The challenges and possibilities of extracellular vesicles as therapeutic vehicles. Eur. J. Pharm. Biopharm. 2019, 144, 50–56. [Google Scholar]
- Cocce, V.; Franze, S.; Brini, A.T.; Gianni, A.B.; Pascucci, L.; Ciusani, E.; Alessandri, G.; Farronato, G.; Cavicchini, L.; Sordi, V.; et al. In vitro anticancer activity of extracellular vesicles (EVs) secreted by gingival mesenchymal stromal cells primed with paclitaxel. Pharmaceutics 2019, 11, 61. [Google Scholar]
- Aziz, M.A.A.E.; Agarwal, K.; Dasari, S.; Mitra, A.A.K. Productive cross-talk with the microenvironment: A critical step in ovarian cancer metastasis. Cancers 2019, 11, 1608. [Google Scholar]
- Cai, Q.; Yan, L.; Xu, Y. Anoikis resistance is a critical feature of highly aggressive ovarian cancer cells. Oncogene 2015, 34, 3315–3324. [Google Scholar] [PubMed] [Green Version]
- Drakes, M.L.; Stiff, P.J. Regulation of ovarian cancer prognosis by immune cells in the tumor microenvironment. Cancers 2018, 10, 302. [Google Scholar]
- Motohara, T.; Masuda, K.; Morotti, M.; Zheng, Y.; El-Sahhar, S.; Chong, K.Y.; Wietek, N.; Alsaadi, A.; Karaminejadranjbar, M.; Hu, Z.; et al. An evolving story of the metastatic voyage of ovarian cancer cells: Cellular and molecular orchestration of the adipose-rich metastatic microenvironment. Oncogene 2019, 38, 2885–2898. [Google Scholar] [PubMed] [Green Version]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Borghese, C.; Casagrande, N.; Corona, G.; Aldinucci, D. Adipose-Derived Stem Cells Primed with Paclitaxel Inhibit Ovarian Cancer Spheroid Growth and Overcome Paclitaxel Resistance. Pharmaceutics 2020, 12, 401. https://doi.org/10.3390/pharmaceutics12050401
Borghese C, Casagrande N, Corona G, Aldinucci D. Adipose-Derived Stem Cells Primed with Paclitaxel Inhibit Ovarian Cancer Spheroid Growth and Overcome Paclitaxel Resistance. Pharmaceutics. 2020; 12(5):401. https://doi.org/10.3390/pharmaceutics12050401
Chicago/Turabian StyleBorghese, Cinzia, Naike Casagrande, Giuseppe Corona, and Donatella Aldinucci. 2020. "Adipose-Derived Stem Cells Primed with Paclitaxel Inhibit Ovarian Cancer Spheroid Growth and Overcome Paclitaxel Resistance" Pharmaceutics 12, no. 5: 401. https://doi.org/10.3390/pharmaceutics12050401